Literature DB >> 7973433

The expression of glutathione transferase mu in patients with inflammatory bowel disease.

E Hertervig1, A Nilsson, J Seidegård.   

Abstract

BACKGROUND: Glutathione transferases (GST) are a group of multifunctional enzymes important in the detoxification of many electrophiles and, in addition, fatty acid hydroperoxides, thus limiting tissue damage from oxidative free radical attack. Of the four classes of GST (alpha, mu, pi, and theta), a class mu isoenzyme, GST mu, is dominantly inherited and is expressed in approximately half of the population. GST mu expression was examined in patients with inflammatory bowel disease and correlated to clinical course, extension, and age of onset of the diseases.
METHODS: GST mu can be measured as GST activity against trans-stilbene oxide. This GST activity was measured in whole blood in 179 patients with ulcerative colitis, 109 patients with Crohn's disease, and 449 age-matched controls.
RESULTS: Frequencies of GST mu expression were as follows: controls (n = 449, 51.2%), mild ulcerative colitis (n = 76, 47.3%), moderate ulcerative colitis (n = 43, 46.5%), and severe ulcerative colitis (characterized by colectomy) (n = 60, 36.7%). This trend was, however, not significant (p = 0.094). Patients with onset of the colitis before the age of 30 years (n = 91) had a lower frequency of GST mu expression (35.2%) than patients with a later onset (n = 88, 52.3%) (p < 0.05). This difference was more pronounced among the colectomized patients (19.4% versus 55.2%) (p < 0.01). In Crohn's disease, patients with colitis had a lower frequency of GST mu expression (n = 29, 31.0%) than controls; however, this was not statistically significant (p = 0.055). No difference was found with regard to age of onset.
CONCLUSION: We conclude that in patients with ulcerative colitis, lack of GST mu is related to early age of onset and a more severe clinical course leading to colectomy.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7973433     DOI: 10.3109/00365529409092501

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  7 in total

Review 1.  Human colonocyte detoxification.

Authors:  W E Roediger; W Babidge
Journal:  Gut       Date:  1997-12       Impact factor: 23.059

2.  GST Theta null genotype is associated with an increased risk for ulcerative colitis: a case-control study and meta-analysis of GST Mu and GST Theta polymorphisms in inflammatory bowel disease.

Authors:  Mark M T J Broekman; Caro Bos; René H M Te Morsche; Frank Hoentjen; Hennie M J Roelofs; Wilbert H M Peters; Geert J A Wanten; Dirk J de Jong
Journal:  J Hum Genet       Date:  2014-09-04       Impact factor: 3.172

3.  Effect of glucagon-like peptide 2 on hepatic, renal, and intestinal disposition of 1-chloro-2,4-dinitrobenzene.

Authors:  Silvina S M Villanueva; Virginia G Perdomo; María L Ruiz; Juan P Rigalli; Agostina Arias; Marcelo G Luquita; Mary Vore; Viviana A Catania; Aldo D Mottino
Journal:  Drug Metab Dispos       Date:  2012-03-27       Impact factor: 3.922

4.  Thiol methyltransferase activity in inflammatory bowel disease.

Authors:  W E Roediger; W J Babidge
Journal:  Gut       Date:  2000-08       Impact factor: 23.059

5.  Genetic polymorphisms in biotransformation enzymes in Crohn's disease: association with microsomal epoxide hydrolase.

Authors:  D J de Jong; E M J van der Logt; A van Schaik; H M J Roelofs; W H M Peters; T H J Naber
Journal:  Gut       Date:  2003-04       Impact factor: 23.059

Review 6.  Pathomechanisms of Oxidative Stress in Inflammatory Bowel Disease and Potential Antioxidant Therapies.

Authors:  Tian Tian; Ziling Wang; Jinhua Zhang
Journal:  Oxid Med Cell Longev       Date:  2017-06-28       Impact factor: 6.543

7.  Association of Glutathione S-Transferase M1 null genotype with inflammatory bowel diseases: A systematic review and meta-analysis.

Authors:  Yu-Jie Zhou; Bao-Lin Zhao; Zheng Qian; Yi Xu; Ya-Qing Ding
Journal:  Medicine (Baltimore)       Date:  2019-11       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.